ALK announces successful outcome of two Phase III clinical studies of the new innovative ragweed tablet. Both studies met the primary efficacy endpoints and the efficacy results were consistent between the two studies. Copenhagen, 2011-08-03 12:53 CEST (GLOBE NEWSWIRE) --
http://www.cisionwire.com/alk-abello-g/r/alk--phase-iii-studies-with-ragweed-allergy-immunotherapy-tablet--ait--meet-primary-endpoints,e249906
This study among others will lead the Food and Drug Administration (FDA) to ultimately approve sublingual immunotherapy (SLIT) for commerial use.
Subscribe to:
Post Comments (Atom)
Mother and daughter getting allergy skin tests. Click on the photo to see a You Tube interview with another parent and child.
No comments:
Post a Comment